This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
240
bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide
University of Minnesota
Minneapolis, Minnesota, United States
Infectious Diseases Institute
Kampala, Uganda
Time to Death
Time frame: 24 Weeks
Functional Status
Modified Rankin score
Time frame: 24 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.